Breaking News, Financial News

Financial Report: AbbVie

HUMIRA sales up 11% in the quarter

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie

4Q Revenues: $5.5 billion (+7%) 

4Q Loss: $810 million (earnings were $1.1 billion 4Q13)

FY Revenues: $20.0 billion (+6%)

FY Earnings: $1.8 billion (earnings were $4.1 billion FY13)

Comments: Growth in the quarter was driven primarily by HUMIRA sales, up 11% to $3.4 billion. Creon sales were $151 million, up 31%. Dyslipidemia sales were $104 million, up 14%. Synagis sales were down 5% to 298 million in the quarter. AndroGel sales declined 20% to $230 million. Earnings were impacted the Shire termination. R&D expenses were $879 million in the quarter.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters